NASDAQ:TARS - Get Free Report )'s stock price reached a new 52-week high during trading on Thursday . The company traded as high as $42.50 and last traded at $39.07, with a volume of 192307 shares trading hands. The stock had previously closed at $37.35.
Get Tarsus Pharmaceuticals alerts:
Sign Up
Analysts Set New Price Targets Several analysts have recently weighed in on the stock. The Goldman Sachs Group raised their price objective on shares of Tarsus Pharmaceuticals from $19.00 to $30.00 and gave the stock a "neutral" rating in a report on Thursday, February 29th. HC Wainwright raised their price target on Tarsus Pharmaceuticals from $50.00 to $57.00 and gave the company a "buy" rating in a report on Wednesday, February 28th. Oppenheimer boosted their price objective on Tarsus Pharmaceuticals from $59.00 to $61.00 and gave the stock an "outperform" rating in a research note on Thursday. Jefferies Financial Group increased their target price on Tarsus Pharmaceuticals from $30.00 to $44.00 and gave the stock a "buy" rating in a report on Wednesday, March 6th. Finally, Barclays lifted their price target on Tarsus Pharmaceuticals from $40.00 to $50.00 and gave the company an "overweight" rating in a report on Wednesday, February 28th. One analyst has rated the stock with a hold rating and seven have issued a buy rating to the stock. According to MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average target price of $48.63.
View Our Latest Research Report on TARS
Tarsus Pharmaceuticals Price Performance The company has a market capitalization of $1.29 billion, a price-to-earnings ratio of -7.79 and a beta of 1.10. The company has a current ratio of 6.93, a quick ratio of 6.85 and a debt-to-equity ratio of 0.15. The company has a 50 day moving average price of $34.32 and a 200 day moving average price of $26.09.
Tarsus Pharmaceuticals (NASDAQ:TARS - Get Free Report ) last posted its quarterly earnings results on Tuesday, February 27th. The company reported ($1.31) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.37) by $0.06. The firm had revenue of $13.08 million during the quarter, compared to the consensus estimate of $4.63 million. During the same quarter in the prior year, the business earned ($0.49) EPS. As a group, equities research analysts forecast that Tarsus Pharmaceuticals, Inc. will post -4.25 earnings per share for the current year.
Insider Transactions at Tarsus Pharmaceuticals In other Tarsus Pharmaceuticals news, insider Aziz Mottiwala sold 4,766 shares of the company's stock in a transaction on Monday, March 18th. The shares were sold at an average price of $30.60, for a total transaction of $145,839.60. Following the completion of the sale, the insider now owns 54,075 shares in the company, valued at approximately $1,654,695. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink . In related news, insider Aziz Mottiwala sold 4,766 shares of the business's stock in a transaction that occurred on Monday, March 18th. The shares were sold at an average price of $30.60, for a total transaction of $145,839.60. Following the completion of the transaction, the insider now owns 54,075 shares in the company, valued at $1,654,695. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website . Also, General Counsel Bryan Wahl sold 4,436 shares of the stock in a transaction on Monday, March 18th. The stock was sold at an average price of $30.60, for a total transaction of $135,741.60. Following the completion of the sale, the general counsel now owns 40,951 shares in the company, valued at $1,253,100.60. The disclosure for this sale can be found here . Insiders sold a total of 24,496 shares of company stock worth $749,578 in the last quarter. 11.54% of the stock is owned by company insiders.
Institutional Trading of Tarsus Pharmaceuticals Several hedge funds have recently added to or reduced their stakes in TARS. RTW Investments LP increased its holdings in shares of Tarsus Pharmaceuticals by 9.4% in the fourth quarter. RTW Investments LP now owns 3,152,341 shares of the company's stock worth $63,835,000 after acquiring an additional 271,640 shares in the last quarter. Vanguard Group Inc. increased its stake in Tarsus Pharmaceuticals by 25.6% during the 3rd quarter. Vanguard Group Inc. now owns 1,551,802 shares of the company's stock worth $27,576,000 after purchasing an additional 316,128 shares in the last quarter. Jennison Associates LLC acquired a new stake in Tarsus Pharmaceuticals during the 1st quarter worth approximately $48,380,000. TFG Asset Management GP Ltd raised its holdings in Tarsus Pharmaceuticals by 30.1% during the 4th quarter. TFG Asset Management GP Ltd now owns 800,000 shares of the company's stock worth $16,200,000 after buying an additional 185,000 shares during the period. Finally, Deerfield Management Company L.P. Series C bought a new position in Tarsus Pharmaceuticals in the third quarter valued at approximately $13,399,000. Institutional investors and hedge funds own 90.01% of the company's stock.
About Tarsus Pharmaceuticals (
Get Free Report )
Tarsus Pharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.
Featured Articles Before you consider Tarsus Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Tarsus Pharmaceuticals wasn't on the list.
While Tarsus Pharmaceuticals currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.
Get This Free Report
